|
Leukemia, Myelocytic, Acute
|
0.070 |
Biomarker
|
disease |
BEFREE |
The breakpoint cluster region-ABL proto-oncogene 1 (<i>BCR-ABL</i>) rearrangement leads to a p210 chimeric protein in typical chronic myeloid leukemia (CML), whereas 17-25% of patients with acute lymphocytic leukemia and 0.9-3% patients with <i>de novo</i> acute myeloid leukemia (AML) carry a p190<sup>BCR-ABL</sup> fusion protein.
|
29151902 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.070 |
Biomarker
|
disease |
BEFREE |
To our knowledge, this is the first reported case of de novo AML in which has p210(BCR/ABL1) occurred as a secondary change of inv(16).
|
23054652 |
2012 |
|
Leukemia, Myelocytic, Acute
|
0.070 |
Biomarker
|
disease |
BEFREE |
All cases were BCR-ABL+ with p210 products detected in all CML cases and a p190 product detected in the AML case.
|
16393682 |
2006 |
|
Leukemia, Myelocytic, Acute
|
0.070 |
Biomarker
|
disease |
BEFREE |
An oligonucleotide microarray was designed for hybridization with products of a multiplex RT-PCR to identify the following translocations: t(9;22)p190, t(4;11), t(12;21), t(1;19), typical for acute lymphoblastic leukemia; t(9;22)p210 for chronic myeloid leukemia; and t(8;21), t(15;17), inv16, typical for acute myeloblastic leukemia.
|
14654544 |
2003 |
|
Leukemia, Myelocytic, Acute
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
In these, we used (1) the human acute myelogenous leukemia (AML) HL-60 cells that are stably transfected with the bcr-abl gene (HL-60/Bcr-Abl) and express p185 Bcr-Abl; and (2) the chronic myelogenous leukemia (CML)-blast crisis K562 cells, which have endogenous expression of p210 Bcr-Abl.
|
9473236 |
1998 |
|
Leukemia, Myelocytic, Acute
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Establishment of a novel human myeloid leukaemia cell line (HNT-34) with t(3;3)(q21;q26), t(9;22)(q34;q11) and the expression of EVI1 gene, P210 and P190 BCR/ABL chimaeric transcripts from a patient with AML after MDS with 3q21q26 syndrome.
|
9266939 |
1997 |
|
Leukemia, Myelocytic, Acute
|
0.070 |
Biomarker
|
disease |
BEFREE |
The shorter p190 protein is associated almost only with ALL and AML, while the protein p210 is present in both chronic phase and blast crisis of CML and also in 50% of Philadelphia-positive (Ph1+) ALL.
|
2247753 |
1990 |